Orthocell awarded US trademark for Ortho-ATI® cell therapy for treatment of chronic tendon injuries
Orthocell Ltd (ASX:OCC) has been awarded the United States Divisional Trade Mark Registration for its Ortho-ATI® cell therapy for the treatment of chronic tendon injuries.
The trademark application, which was accepted and registered in June 2020, will remain in force for an initial period of 10 years and may be renewed for successive periods of 10 years thereafter.
Managing director Paul Anderson said: “We are delighted to receive this important trademark within the United States, which complements our strong intellectual property portfolio and our ongoing efforts to bring this exciting technology into the US market.
2019 Annual Quality Study[hhmc]
Early this month, the company released its 2019 Annual Quality Study, which indicated an 87.5% patient satisfaction rating using Ortho-ATI® cell therapy for the treatment of chronic tendon injuries of the shoulder and a 74.3% patient satisfaction rating in all patient groups including, elbow, hip, knee and ankle.
It indicated that 87.5% of shoulder patients were satisfied with how Ortho-ATI® relieved symptoms (ie chronic pain) and improved ability to perform everyday activities at home and at work.
Patient case studies[hhmc]
One of the patient case studies involved well-known AFL star, Daniel Kerr, who played 220 games for the West Coast Eagles between 2001 and 2013.
At the age of 28, he suffered a complete hamstring ruptureRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
